Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com - Citi has initiated coverage on Caris Life Sciences Inc (NASDAQ:CAI) with a Buy rating and a price target of $34.00, representing a 28% upside from the current price of $26.51. The $7.4 billion market cap company’s unique financial profile stands out among diagnostic peers.
The research firm highlighted Caris Life Sciences’ use of molecular information and artificial intelligence/machine learning to power commercial products like MI Profile and Caris Assure. According to InvestingPro data, the company’s revenue reached $452.5 million in the last twelve months, with an impressive gross profit margin of 46.7%.
Caris currently focuses primarily on clinical therapy selection while also providing services to biopharmaceutical companies, with plans to expand its pipeline to address the entire cancer care continuum from early detection to therapy selection and minimal residual disease monitoring.
Citi projects Caris to achieve an adjusted EBITDA margin of 13.6% in fiscal year 2026 and 18.2% in fiscal year 2027, demonstrating what it describes as a "healthy profitability ramp and leaner opex structure."
While trading at approximately 7.9 times Citi’s projected fiscal year 2026 sales—a premium compared to industry peers—the firm believes this valuation is justified given Caris Life Sciences’ strategy for accelerated profitability and elevated growth profile. InvestingPro’s Financial Health Score indicates a "Fair" rating, with revenue forecast to grow 20% in fiscal year 2025.
In other recent news, Caris Life Sciences has been the focus of multiple analyst firms, with several initiating coverage on the company. TD Cowen has given Caris a Buy rating with a price target of $32.00, citing a potential 54% compound annual growth rate in sales from 2024 to 2026 and an EBIT margin expansion over 21% by 2027. JPMorgan also started coverage with an Overweight rating and a $31.00 price target, projecting a 33.3% revenue compound annual growth rate from 2025 to 2028 and expecting the company to reach positive adjusted EBITDA by the fourth quarter of 2025. Guggenheim has rated Caris as a Buy, focusing on its comprehensive therapy selection platform and extensive database as key differentiators in the precision medicine sector. BTIG has set a price target of $38.00, highlighting Caris as a leader in precision oncology lab testing and noting its FDA-approved tissue-based assay. BofA Securities also initiated a Buy rating with a $31.00 price target, forecasting a 41% sales compound annual growth rate from fiscal year 2024 to 2027 and a 28% adjusted EBITDA margin in fiscal year 2027. These developments underscore Caris Life Sciences’ strong positioning in the molecular diagnostics and precision medicine markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.